Floatz logo

Zanubrutinib

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical CenterSmall moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

107 Active assets in the Relapsed/Refractory Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Selinexor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3BB
DEXAMETHASONE
City of Hope Medical Center
Phase 2/3BB
Ifosfamide
University of California, Davis
Phase 3BB
ETOPOSIDE
University of California, Davis
Phase 3BB
Axicabtagene Ciloleucel
Zhujiang Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Zanubrutinib is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
splenic marginal zone lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
marginal zone lymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →